Home

EDV
EDV
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
previous arrowprevious arrow
next arrownext arrow
Shadow

 

Breaking News

EnGeneIC granted FDA Fast-Track Designation for Novel Armed Nanocell Drug Conjugate Pancreatic Cancer Therapeutic.

EnGeneIC has achieved a significant milestone with the granting of FDA “Fast-Track” designation for its pancreatic cancer therapeutic.

Click here for more news. 

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Click for full story

Works against mutant strains including Delta & Omicron. No need for refrigeration during transport and storage. No added stabilisers or chemicals. Safety and immune response clinical trial recruiting now in Melbourne, Sydney & Perth to follow. Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.